The Advanced Non-Squamous & Squamous NSCLC Pipeline Insight 2023 report by DelveInsight offers a thorough global overview of Advanced Non-Squamous & Squamous NSCLC treatments, including those already in the market, as well as those in different phases of clinical development. Prominent pharmaceutical firms are dedicated to progressing the Advanced Non-Squamous & Squamous NSCLC pipeline landscape and fostering the potential growth of Advanced Non-Squamous & Squamous NSCLC therapeutic advancements.

 

Key Takeaways from the Advanced Non-Squamous & Squamous NSCLC Pipeline Report

• DelveInsight’s Advanced Non-Squamous & Squamous NSCLC pipeline report depicts a robust space with 9+ active players working to develop 10+ pipeline therapies for Advanced Non-Squamous & Squamous NSCLC treatment.
• The leading companies working in the Advanced Non-Squamous & Squamous NSCLC market include Jiangsu Alphamab Biopharmaceuticals, Jiangsu HengRui Medicine, Daiichi Sankyo Company, Genentech, Sinocelltech, Merck KGaA, Mirati Therapeutics, Ability Pharmaceuticals, Axelar AB, and others.
• Promising Advanced Non-Squamous & Squamous NSCLC Pipeline Therapies in the various stages of development include Pyrotinib, Docetaxel, Tiragolumab, Atezolizumab, Bevacizumab, Pemetrexed, TQB2450 Injection, Cisplatin (or carboplatin), Bevacizumab-Pfizer, Carboplatin, Paclitaxel, PM8002, T-DXd, Amivantamab, Lazertinib, Zirabev, and others.
• On March 2023, Jiangsu HengRui Medicine Co., Ltd. announced a study of Phase 3 Clinical Trials for Pyrotinib and Docetaxel. This is a randomized, positive-controlled, open-label, international multicenter, Phase 3 clinical study to compare the efficacy and safety of pyrotinib versus docetaxel in patients with advanced non-squamous NSCLC harboring a HER2 exon 20 mutation who failed platinum based chemotherapy.
• On May 2023, Georgetown University announced a study of Phase 2 Clinical Trials for Tiragolumab, Atezolizumab, and Bevacizumab. To evaluate the efficacy of tiragolumab with atezolizumab and bevacizumab in previously-treated advanced non-squamous NSCLC.
• On May 2023, BeiGene announced a study of Phase 3 Clinical Trials for Tislelizumab,Cisplatin or Carboplatin ,Pemetrexed. A Phase 3, Open-Label, Multi-Center, Randomized Study to Investigate the Efficacy and Safety of Tislelizumab (BGB-A317) (Anti-PD1 Antibody) Combined With Platinum-Pemetrexed Versus Platinum-Pemetrexed Alone as First-line Treatment for Participants With Stage IIIB or IV Non-Squamous Non-Small Cell Lung Cancer. 45 sites will be involved in China, 320 subjects will be enrolled.
• On July 2023, Biotheus Inc. announced a study of Phase 2 & 3 Clinical Trials for PM8002 and Carboplatin. PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This is a phase II/III study to evaluate the efficacy and safety of PM8002 in combination with pemetrexed and carboplatin in patients with EGFR-mutant locally advanced or metastatic non-squamous NSCLC who have failed to EGFR-TKI treatment.

 

Request a sample and discover the recent advances in Advanced Non-Squamous & Squamous NSCLC Treatment Drugs @ Advanced Non-Squamous & Squamous NSCLC Infection Pipeline Report

The Advanced Non-Squamous & Squamous NSCLC pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Advanced Non-Squamous & Squamous NSCLC drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Advanced Non-Squamous & Squamous NSCLC clinical trial landscape.

 

Advanced Non-Squamous & Squamous NSCLC Overview

Lung cancer is one of the most common types of cancer across the globe and among the leading causes of cancer-related deaths. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers and is further classified into squamous NSCLC and non-squamous NSCLC (includes large cell histologies and adenocarcinoma).

 

Find out more about Advanced Non-Squamous & Squamous NSCLC Treatment Drugs @ Drugs for Advanced Non-Squamous & Squamous NSCLC Treatment

 

Advanced Non-Squamous & Squamous NSCLC Emerging Drugs Profile

• KN-046: Jiangsu Alphamab Biopharmaceuticals
• Pyrotinib: Jiangsu HengRui Medicine

 

Advanced Non-Squamous & Squamous NSCLC Pipeline Therapeutics Assessment

There are approx. 9+ key companies which are developing the therapies for Advanced Non-Squamous & Squamous NSCLC. The Advanced Non-Squamous & Squamous NSCLC companies which have their Advanced Non-Squamous & Squamous NSCLC drug candidates in the most advanced stage, i.e. phase II include, Jiangsu Alphamab Biopharmaceuticals.

 

Learn more about the emerging Advanced Non-Squamous & Squamous NSCLC Pipeline Therapies @ Advanced Non-Squamous & Squamous NSCLC Clinical Trials Assessment

 

Scope of the Advanced Non-Squamous & Squamous NSCLC Pipeline Report

• Coverage- Global
• Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Advanced Non-Squamous & Squamous NSCLC Companies- Jiangsu Alphamab Biopharmaceuticals, Jiangsu HengRui Medicine, Daiichi Sankyo Company, Genentech, Sinocelltech, Merck KGaA, Mirati Therapeutics, Ability Pharmaceuticals, Axelar AB, and others.
• Advanced Non-Squamous & Squamous NSCLC Pipeline Therapies- Pyrotinib, Docetaxel, Tiragolumab, Atezolizumab, Bevacizumab, Pemetrexed, TQB2450 Injection, Cisplatin (or carboplatin), Bevacizumab-Pfizer, Carboplatin, Paclitaxel, PM8002, T-DXd, Amivantamab, Lazertinib, Zirabev, and others.

 

Dive deep into rich insights for new drugs for Advanced Non-Squamous & Squamous NSCLC Treatment, Visit @ Advanced Non-Squamous & Squamous NSCLC Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Advanced Non-Squamous & Squamous NSCLC: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Advanced Non-Squamous & Squamous NSCLC – DelveInsight’s Analytical Perspective
7. Late Stage Products (Preregistration)
8. KN-046: Jiangsu Alphamab Biopharmaceuticals
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Zuranolone: SAGE Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. ABTL0812: Ability Pharmaceuticals
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Advanced Non-Squamous & Squamous NSCLC Key Companies
21. Advanced Non-Squamous & Squamous NSCLC Key Products
22. Advanced Non-Squamous & Squamous NSCLC- Unmet Needs
23. Advanced Non-Squamous & Squamous NSCLC- Market Drivers and Barriers
24. Advanced Non-Squamous & Squamous NSCLC- Future Perspectives and Conclusion
25. Advanced Non-Squamous & Squamous NSCLC Analyst Views
26. Appendix

 

For further information on the Advanced Non-Squamous & Squamous NSCLC pipeline therapeutics, reach out to Advanced Non-Squamous & Squamous NSCLC Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting